



# NEWS RELEASE

## FOR IMMEDIATE RELEASE

### Contact:

Sheryl Seapy, Pure Communications, Inc.  
(949) 608-0841

### **Data on Foundation Medicine's Comprehensive Cancer Diagnostic Test Presented at 2011 European Multidisciplinary Cancer Congress**

**CAMBRIDGE, Mass. and STOCKHOLM, Sweden – September 22, 2011 – [Foundation Medicine, Inc.](#)**, a cancer diagnostics company that aims to bring comprehensive cancer genome analysis to routine care, today announced that the company will present data using its comprehensive Next-Generation Sequencing (NGS) approach to identify novel mutations with clinical utility in routine cancer specimens at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden. These data will be presented by Gary Palmer, M.D., J.D., M.B.A., M.P.H., senior vice president, medical affairs and commercial development, Foundation Medicine, in an oral presentation on Sunday, September 25, 2011, at 9:00 a.m. (CEST) during the “personalized medicine” proffered paper session, abstract number 800.

“We look forward to sharing data on our comprehensive pan-cancer diagnostic test with members of the European clinical oncology community,” said Dr. Palmer. “As additional mutations driving patients’ cancers are discovered and more targeted cancer therapies are developed to target these specific mutations, there is an even greater need for comprehensive cancer genome analysis to help inform treatment recommendations. Foundation Medicine’s test detects genomic alterations in relevant cancer genes, including many that are missed using conventional hot spot analysis, at a level of sensitivity and specificity that makes this a clinically relevant test. Using NGS for comprehensive molecular profiling of small amounts of paraffin-embedded cancer tissue, we are able to determine patients’ cancer subtypes to inform targeted therapy selection for each patient.”

### **About Foundation Medicine**

Foundation Medicine is dedicated to the development of a comprehensive diagnostic test that improves cancer care by helping physicians personalize treatment for their patients. Foundation Medicine’s laboratory test is being designed to accommodate a broad landscape of cancer genome information and a growing repertoire of more targeted treatments and clinical research opportunities. Foundation Medicine’s test will assist physicians to make prompt and informed determinations about the best cancer treatments and clinical trial options for each patient, taking into account each patient’s unique cancer-associated alterations alongside publicly available scientific and medical information. The company’s founding advisors are world leaders in genome technology, cancer biology and medical oncology; they, alongside clinicians, biotech and molecular diagnostics industry leaders, are working to harness emerging technologies to develop unparalleled tests that will identify and interpret an ever-growing set of actionable

genomic alterations, truly enabling personalized cancer medicine. For more information, please visit the company's website at [www.foundationmedicine.com](http://www.foundationmedicine.com).

###